Proposed acquisition strengthens Pharming’s late-stage pipeline with a potential first-in-disease asset

Abliva’s lead product KL1333 is currently in a pivotal clinical trial, with a positive interim analysis achieved, in mitochondrial DNA-driven primary mitochondrial diseases

Total transaction value of approximately US$66.1 million

No external funding required to fund acquisition and KL1333 development costs

Pharming to host a conference call on Monday, December 16, 2024 at 14:00 CET (8:00 am EST)

Pharming Group N.V. (“Pharming” or “the Company”) (EURONEXT Amsterdam: PHARM/Nasdaq: PHAR) today announced a recommended public cash offer to the shareholders of Abliva AB (“Abliva”) to acquire all issued and outstanding shares of Abliva. Pharming, through its wholly-owned subsidiary Pharming Technologies B.V., offers the shareholders SEK 0.45 in cash per share in Abliva. The transaction is valued at approximately US$66.1 million. 

For information in relation to the Offer, please refer to www.raredisease-offer.com.